
Global Quadrivalent Meningococcal Vaccine Market Growth 2023-2029
Description
Global Quadrivalent Meningococcal Vaccine Market Growth 2023-2029
The global Quadrivalent Meningococcal Vaccine market size is projected to grow from US$ 181 million in 2022 to US$ 273.9 million in 2029; it is expected to grow at a CAGR of 6.1% from 2023 to 2029.
Many countries have implemented meningococcal vaccination programs, especially targeting high-risk groups such as infants, adolescents and university students. Inclusion or recommendation of quadrivalent meningococcal vaccines in national immunization schedules can significantly influence the market demand.
The meningococcal quadrivalent vaccine protects against 4 types of meningococcus: types A, C, Y, and W.
LPI (LP Information)' newest research report, the “Quadrivalent Meningococcal Vaccine Industry Forecast” looks at past sales and reviews total world Quadrivalent Meningococcal Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Quadrivalent Meningococcal Vaccine sales for 2023 through 2029. With Quadrivalent Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Quadrivalent Meningococcal Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Quadrivalent Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Quadrivalent Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Quadrivalent Meningococcal Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Quadrivalent Meningococcal Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Quadrivalent Meningococcal Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Quadrivalent Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Polysaccharide Vaccine
Conjugate Vaccine
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi-Pasteur
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Quadrivalent Meningococcal Vaccine market?
What factors are driving Quadrivalent Meningococcal Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Quadrivalent Meningococcal Vaccine market opportunities vary by end market size?
How does Quadrivalent Meningococcal Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
94 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Quadrivalent Meningococcal Vaccine by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Quadrivalent Meningococcal Vaccine by Country/Region, 2018, 2022 & 2029
- 2.2 Quadrivalent Meningococcal Vaccine Segment by Type
- 2.2.1 Polysaccharide Vaccine
- 2.2.2 Conjugate Vaccine
- 2.3 Quadrivalent Meningococcal Vaccine Sales by Type
- 2.3.1 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2023)
- 2.3.2 Global Quadrivalent Meningococcal Vaccine Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Type (2018-2023)
- 2.4 Quadrivalent Meningococcal Vaccine Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.5 Quadrivalent Meningococcal Vaccine Sales by Application
- 2.5.1 Global Quadrivalent Meningococcal Vaccine Sale Market Share by Application (2018-2023)
- 2.5.2 Global Quadrivalent Meningococcal Vaccine Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Application (2018-2023)
- 3 Global Quadrivalent Meningococcal Vaccine by Company
- 3.1 Global Quadrivalent Meningococcal Vaccine Breakdown Data by Company
- 3.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Company (2018-2023)
- 3.1.2 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Company (2018-2023)
- 3.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Company (2018-2023)
- 3.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Company (2018-2023)
- 3.2.2 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Company (2018-2023)
- 3.3 Global Quadrivalent Meningococcal Vaccine Sale Price by Company
- 3.4 Key Manufacturers Quadrivalent Meningococcal Vaccine Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Quadrivalent Meningococcal Vaccine Product Location Distribution
- 3.4.2 Players Quadrivalent Meningococcal Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
- 4 World Historic Review for Quadrivalent Meningococcal Vaccine by Geographic Region
- 4.1 World Historic Quadrivalent Meningococcal Vaccine Market Size by Geographic Region (2018-2023)
- 4.1.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Quadrivalent Meningococcal Vaccine Market Size by Country/Region (2018-2023)
- 4.2.1 Global Quadrivalent Meningococcal Vaccine Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Quadrivalent Meningococcal Vaccine Sales Growth
- 4.4 APAC Quadrivalent Meningococcal Vaccine Sales Growth
- 4.5 Europe Quadrivalent Meningococcal Vaccine Sales Growth
- 4.6 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales Growth
- 5 Americas
- 5.1 Americas Quadrivalent Meningococcal Vaccine Sales by Country
- 5.1.1 Americas Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
- 5.1.2 Americas Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
- 5.2 Americas Quadrivalent Meningococcal Vaccine Sales by Type
- 5.3 Americas Quadrivalent Meningococcal Vaccine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Quadrivalent Meningococcal Vaccine Sales by Region
- 6.1.1 APAC Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023)
- 6.1.2 APAC Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023)
- 6.2 APAC Quadrivalent Meningococcal Vaccine Sales by Type
- 6.3 APAC Quadrivalent Meningococcal Vaccine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
- 7 Europe
- 7.1 Europe Quadrivalent Meningococcal Vaccine by Country
- 7.1.1 Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
- 7.1.2 Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
- 7.2 Europe Quadrivalent Meningococcal Vaccine Sales by Type
- 7.3 Europe Quadrivalent Meningococcal Vaccine Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Quadrivalent Meningococcal Vaccine by Country
- 8.1.1 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Type
- 8.3 Middle East & Africa Quadrivalent Meningococcal Vaccine Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Quadrivalent Meningococcal Vaccine
- 10.3 Manufacturing Process Analysis of Quadrivalent Meningococcal Vaccine
- 10.4 Industry Chain Structure of Quadrivalent Meningococcal Vaccine
- 11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Quadrivalent Meningococcal Vaccine Distributors
- 11.3 Quadrivalent Meningococcal Vaccine Customer
- 12 World Forecast Review for Quadrivalent Meningococcal Vaccine by Geographic Region
- 12.1 Global Quadrivalent Meningococcal Vaccine Market Size Forecast by Region
- 12.1.1 Global Quadrivalent Meningococcal Vaccine Forecast by Region (2024-2029)
- 12.1.2 Global Quadrivalent Meningococcal Vaccine Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Quadrivalent Meningococcal Vaccine Forecast by Type
- 12.7 Global Quadrivalent Meningococcal Vaccine Forecast by Application
- 13 Key Players Analysis
- 13.1 Sanofi-Pasteur
- 13.1.1 Sanofi-Pasteur Company Information
- 13.1.2 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.1.3 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Sanofi-Pasteur Main Business Overview
- 13.1.5 Sanofi-Pasteur Latest Developments
- 13.2 Walvax
- 13.2.1 Walvax Company Information
- 13.2.2 Walvax Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.2.3 Walvax Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Walvax Main Business Overview
- 13.2.5 Walvax Latest Developments
- 13.3 Chengdu Kanghua Biological Products Co., Ltd.
- 13.3.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
- 13.3.2 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.3.3 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
- 13.3.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
- 13.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
- 13.4.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
- 13.4.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.4.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Main Business Overview
- 13.4.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Latest Developments
- 13.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
- 13.5.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
- 13.5.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.5.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.5.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Main Business Overview
- 13.5.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Latest Developments
- 13.6 Beijing Institute of Biological Products Co., Ltd.
- 13.6.1 Beijing Institute of Biological Products Co., Ltd. Company Information
- 13.6.2 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.6.3 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.6.4 Beijing Institute of Biological Products Co., Ltd. Main Business Overview
- 13.6.5 Beijing Institute of Biological Products Co., Ltd. Latest Developments
- 13.7 CanSino Biological Co., Ltd.
- 13.7.1 CanSino Biological Co., Ltd. Company Information
- 13.7.2 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.7.3 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.7.4 CanSino Biological Co., Ltd. Main Business Overview
- 13.7.5 CanSino Biological Co., Ltd. Latest Developments
- 13.8 Hualan Biological Vaccine Co., Ltd.
- 13.8.1 Hualan Biological Vaccine Co., Ltd. Company Information
- 13.8.2 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.8.3 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.8.4 Hualan Biological Vaccine Co., Ltd. Main Business Overview
- 13.8.5 Hualan Biological Vaccine Co., Ltd. Latest Developments
- 13.9 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
- 13.9.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
- 13.9.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolios and Specifications
- 13.9.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.9.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Main Business Overview
- 13.9.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Latest Developments
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.